Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5157740 | 0.90 | MRGPRX4 (0.43) | LMNAGCGRCYP2B6MEN1KMT2A | |
| SCHEMBL5157616 | 0.89 | LMNA (0.41) | LMNAGCGRCTSDMEN1KMT2A | |
| SCHEMBL5160409 | 0.89 | LMNA (0.41) | LMNAGCGRCYP2B6CTSDMEN1 | |
| SCHEMBL5157206 | 0.87 | CTSD (0.41) | LMNACTSDMEN1KMT2AL3MBTL1 | |
| SCHEMBL5155145 | 0.87 | CYP2B6 (0.39) | LMNACYP2B6CTSDMEN1KMT2A | |
| SCHEMBL5158936 | 0.87 | SMN1; SMN2 (0.41) | CYP2B6MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5157179 | 0.86 | NPC1 (0.46) | CTSDMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6815835 | 0.85 | ALDH1A1 (0.47) | LMNACTSDMEN1KMT2AMAPT | |
| SCHEMBL5157309 | 0.83 | LMNA (0.38) | LMNAGCGRCTSDMEN1KMT2A | |
| SCHEMBL5154362 | 0.81 | MRGPRX4 (0.43) | LMNAGCGRMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189873-B2 | Propargylether derivatives, a process for their preparation and their use for controlling phytopathogenic microorganisms | SYNGENTA CORP PROTECTION, INC. (US) | 2007-03-13 | — | — | US | claimed |
| EP-1549609-B1 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | SYNGENTA PARTICIPATIONS AG (CH) | 2007-01-24 | — | — | EP | claimed |
| US-20060167316-A1 | Propargylether derivatives, a process for their preparation and their use for controlling phytopathogenic microorganisms | SYNGENTA CROP PROTECTION, INC. | 2006-07-27 | — | — | US | claimed |
| EP-1549609-A2 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | Syngenta Participations AG (CH) | 2005-07-06 | — | — | EP | claimed |
| WO-2004033413-A2 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | SYNGENTA PARTICIPATIONS AG (CH) | 2004-04-22 | — | — | WO | claimed |
| US-7189873-B2 | Propargylether derivatives, a process for their preparation and their use for controlling phytopathogenic microorganisms | SYNGENTA CORP PROTECTION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1549609-B1 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | SYNGENTA PARTICIPATIONS AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| US-20060167316-A1 | Propargylether derivatives, a process for their preparation and their use for controlling phytopathogenic microorganisms | SYNGENTA CROP PROTECTION, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1549609-A2 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | Syngenta Participations AG (CH) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004033413-A2 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | SYNGENTA PARTICIPATIONS AG (CH) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167316-A1 | Propargylether derivatives, a process for their preparation and their use for controlling phytopathogenic microorganisms | GRHPR, CBR3, CYP8B1 | LMNA 2482/4885GCGR 467/4885CYP2B6 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.